NAUT vs. PACB, SEER, AKYA, BCAB, ORIC, EYPT, AFMD, TALS, QTRX, and VBIV
Should you be buying Nautilus Biotechnology stock or one of its competitors? The main competitors of Nautilus Biotechnology include Pacific Biosciences of California (PACB), Seer (SEER), Akoya Biosciences (AKYA), BioAtla (BCAB), ORIC Pharmaceuticals (ORIC), EyePoint Pharmaceuticals (EYPT), Affimed (AFMD), Talaris Therapeutics (TALS), Quanterix (QTRX), and VBI Vaccines (VBIV). These companies are all part of the "medical" sector.
Nautilus Biotechnology (NASDAQ:NAUT) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.
Pacific Biosciences of California received 442 more outperform votes than Nautilus Biotechnology when rated by MarketBeat users. Likewise, 67.32% of users gave Pacific Biosciences of California an outperform vote while only 16.67% of users gave Nautilus Biotechnology an outperform vote.
In the previous week, Pacific Biosciences of California had 6 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 8 mentions for Pacific Biosciences of California and 2 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 1.88 beat Pacific Biosciences of California's score of 0.63 indicating that Nautilus Biotechnology is being referred to more favorably in the media.
Nautilus Biotechnology has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500.
50.7% of Nautilus Biotechnology shares are owned by institutional investors. 40.5% of Nautilus Biotechnology shares are owned by company insiders. Comparatively, 1.4% of Pacific Biosciences of California shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Nautilus Biotechnology presently has a consensus target price of $6.00, indicating a potential upside of 134.38%. Pacific Biosciences of California has a consensus target price of $6.59, indicating a potential upside of 259.18%. Given Pacific Biosciences of California's stronger consensus rating and higher possible upside, analysts clearly believe Pacific Biosciences of California is more favorable than Nautilus Biotechnology.
Nautilus Biotechnology has a net margin of 0.00% compared to Pacific Biosciences of California's net margin of -148.13%. Nautilus Biotechnology's return on equity of -24.94% beat Pacific Biosciences of California's return on equity.
Nautilus Biotechnology has higher earnings, but lower revenue than Pacific Biosciences of California. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.
Summary
Pacific Biosciences of California beats Nautilus Biotechnology on 10 of the 17 factors compared between the two stocks.
Get Nautilus Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAUT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NAUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nautilus Biotechnology Competitors List
Related Companies and Tools
